1. Home
  2. MURA vs SCLX Comparison

MURA vs SCLX Comparison

Compare MURA & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MURA
  • SCLX
  • Stock Information
  • Founded
  • MURA 2013
  • SCLX 2011
  • Country
  • MURA Ireland
  • SCLX United States
  • Employees
  • MURA N/A
  • SCLX N/A
  • Industry
  • MURA
  • SCLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MURA
  • SCLX Health Care
  • Exchange
  • MURA Nasdaq
  • SCLX Nasdaq
  • Market Cap
  • MURA 67.4M
  • SCLX 61.5M
  • IPO Year
  • MURA N/A
  • SCLX N/A
  • Fundamental
  • Price
  • MURA $4.05
  • SCLX $0.33
  • Analyst Decision
  • MURA Strong Buy
  • SCLX Strong Buy
  • Analyst Count
  • MURA 5
  • SCLX 4
  • Target Price
  • MURA $16.00
  • SCLX $14.00
  • AVG Volume (30 Days)
  • MURA 135.3K
  • SCLX 184.3K
  • Earning Date
  • MURA 03-25-2025
  • SCLX 03-11-2025
  • Dividend Yield
  • MURA N/A
  • SCLX N/A
  • EPS Growth
  • MURA N/A
  • SCLX N/A
  • EPS
  • MURA N/A
  • SCLX N/A
  • Revenue
  • MURA N/A
  • SCLX $55,152,000.00
  • Revenue This Year
  • MURA N/A
  • SCLX $24.19
  • Revenue Next Year
  • MURA N/A
  • SCLX $109.90
  • P/E Ratio
  • MURA N/A
  • SCLX N/A
  • Revenue Growth
  • MURA N/A
  • SCLX 22.02
  • 52 Week Low
  • MURA $2.87
  • SCLX $0.32
  • 52 Week High
  • MURA $5.62
  • SCLX $2.63
  • Technical
  • Relative Strength Index (RSI)
  • MURA 51.01
  • SCLX 30.09
  • Support Level
  • MURA $4.13
  • SCLX $0.33
  • Resistance Level
  • MURA $4.39
  • SCLX $0.36
  • Average True Range (ATR)
  • MURA 0.25
  • SCLX 0.03
  • MACD
  • MURA -0.02
  • SCLX -0.00
  • Stochastic Oscillator
  • MURA 42.50
  • SCLX 8.90

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: